Australia-based Paradigm Biopharmaceuticals has reported positive top-line results from a Phase IIa clinical trial of pentosan polysulfate (PPS) conducted in patients with a ruptured anterior cruciate ligament (ACL) injury and a bone marrow lesion (BML).

The open-label trial has met the primary endpoint of safety and tolerability with a statistically significant decrease in BML volume and effusion-synovitis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Conducted in 11 patients, the trial assessed the safety, tolerability and efficacy of a course of six intramuscular PPS injections over a period of three weeks.

The trial recruited patients who developed bone marrow lesions following ACL injuries.

Nine out of the total participants are reported to have completed the trial without any serious adverse events, indicating the potential of PPS to significantly improve recovery from the injury.

“The open-label trial has met the primary endpoint of safety and tolerability with a statistically significant decrease in BML volume and effusion-synovitis.”

Paradigm has also provided an update on two of its other Phase II trials of PPS being conducted for the treatment of arthritis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A randomised, double-blind, placebo-controlled, multi-centre Phase IIb trial has completed 23% of patient enrolment from two sites and plans to initiate three additional sites from January next year.

With results expected in the fourth quarter of next year, the trial is seeking to investigate PPS in patients with knee osteoarthritis and concurrent subchondral bone marrow lesions.

Another Phase IIa trial is set to assess the safety, tolerability and effects of PPS in a total of 24 subjects with Ross River virus (RRV) induced arthralgia (painful joints) at four centres in Victoria and Queensland.

The trial has completed 60% of its enrolment and is scheduled to report results by mid-next year.